Senior Director, Regulatory Affairs, Spain And Portugal

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers.

The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.

The company's RAS(ON) inhibitors daraxonrasib (RMC), a RAS(ON) multi-selective inhibitor; elironrasib (RMC), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC), a RAS(ON) G12D-selective inhibitor; and RMC, a RAS(ON) G12V-selective inhib…